U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07076680) titled 'A Real-World Study of Elacestrant in Patients With HR+/HER2- Advanced Breast Cancer and ESR1 Mutations' on June 17.
Brief Summary: The goal of this observational study is to learn about the safety and effectiveness of elacestrant in people with advanced breast cancer that is hormone receptor-positive (HR+), HER2-negative (HER2-), and has a mutation in the ESR1 gene.
The main questions it aims to answer are:
How safe is elacestrant when used in real-world clinical settings?
How well does elacestrant work in controlling disease in people with ESR1 mutations?
Participants will:
Already be prescribed elacestrant by their doctor as ...